BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)

399 Royal Avenue
Kelowna, BC, V1Y 5L3

Clinical Trial Unit Manager
Agnes Sauter
250-712-3927
Agnes.Sauter@bccancer.bc.ca

Breast

RUBY: Reducing the bUrden of Breast cancer in Young women 

Cancer Type
Breast
Recruiting Dates
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Victoria
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
BC Cancer - Prince George (Centre for the North)
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Abbotsford
Open Recruiting Date
View on ClinicalTrials.gov

BEGONIA: A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple 

Cancer Type
Breast
Phase II
Recruiting Dates
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
View on ClinicalTrials.gov

PBSI: Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant

Cancer Type
Breast
Recruiting Dates
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
View on ClinicalTrials.gov

FINER: A Double-Blind Placebo-Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Cancer Type
Breast
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
BC Cancer - Surrey
Open Recruiting Date
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
View on ClinicalTrials.gov

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

Cancer Type
Breast
Phase I
Recruiting Dates
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
Open Recruiting Date
View on ClinicalTrials.gov
Back to top